187 related articles for article (PubMed ID: 20812280)
1. Effect of isolated fractions of Harpagophytum procumbens D.C. (devil's claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay.
Anauate MC; Torres LM; de Mello SB
Phytother Res; 2010 Sep; 24(9):1365-9. PubMed ID: 20812280
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of iNOS expression in rat mesangial cells by special extracts of Harpagophytum procumbens derives from harpagoside-dependent and independent effects.
Kaszkin M; Beck KF; Koch E; Erdelmeier C; Kusch S; Pfeilschifter J; Loew D
Phytomedicine; 2004 Nov; 11(7-8):585-95. PubMed ID: 15636171
[TBL] [Abstract][Full Text] [Related]
3. Effects of Devil's Claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/P-glycoprotein.
Romiti N; Tramonti G; Corti A; Chieli E
Phytomedicine; 2009 Dec; 16(12):1095-100. PubMed ID: 19577448
[TBL] [Abstract][Full Text] [Related]
4. Effect of the major glycosides of Harpagophytum procumbens (Devil's Claw) on epidermal cyclooxygenase-2 (COX-2) in vitro.
Abdelouahab N; Heard C
J Nat Prod; 2008 May; 71(5):746-9. PubMed ID: 18412394
[TBL] [Abstract][Full Text] [Related]
5. Alteration of anti-inflammatory activity of Harpagophytum procumbens (devil's claw) extract after external metabolic activation with S9 mix.
Hostanska K; Melzer J; Rostock M; Suter A; Saller R
J Pharm Pharmacol; 2014 Nov; 66(11):1606-14. PubMed ID: 25175765
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of devil's claw (secondary root of Harpagophytum procumbens) extract and harpagoside on cytokine production in mouse macrophages.
Inaba K; Murata K; Naruto S; Matsuda H
J Nat Med; 2010 Apr; 64(2):219-22. PubMed ID: 20177800
[TBL] [Abstract][Full Text] [Related]
7. Harpagoside Content in Devil's Claw Extracts.
Kondamudi N; Turner MW; McDougal OM
Nat Prod Commun; 2016 Sep; 11(9):1215-1216. PubMed ID: 30807002
[TBL] [Abstract][Full Text] [Related]
8. Molecular targets of the antiinflammatory Harpagophytum procumbens (devil's claw): inhibition of TNFα and COX-2 gene expression by preventing activation of AP-1.
Fiebich BL; Muñoz E; Rose T; Weiss G; McGregor GP
Phytother Res; 2012 Jun; 26(6):806-11. PubMed ID: 22072539
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the relative antiinflammatory efficacies of six commercial preparations of Harpagophytum procumbens (Devil's Claw).
Ouitas NA; Heard C
Phytother Res; 2010 Mar; 24(3):333-8. PubMed ID: 19610038
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of harpagoside in horses after intragastric administration of a Devil's claw (Harpagophytum procumbens) extract.
Axmann S; Hummel K; Nöbauer K; Razzazi-Fazeli E; Zitterl-Eglseer K
J Vet Pharmacol Ther; 2019 Jan; 42(1):37-44. PubMed ID: 30242850
[TBL] [Abstract][Full Text] [Related]
11. Iridoid glycosides from Harpagophytum procumbens D.C. (devil's claw).
Qi J; Chen JJ; Cheng ZH; Zhou JH; Yu BY; Qiu SX
Phytochemistry; 2006 Jul; 67(13):1372-7. PubMed ID: 16857222
[TBL] [Abstract][Full Text] [Related]
12. The Fight against Infection and Pain: Devil's Claw (
Gxaba N; Manganyi MC
Molecules; 2022 Jun; 27(11):. PubMed ID: 35684573
[No Abstract] [Full Text] [Related]
13. Isolation and anti-inflammatory activity evaluation of triterpenoids and a monoterpenoid glycoside from Harpagophytum procumbens.
Qi J; Li N; Zhou JH; Yu BY; Qiu SX
Planta Med; 2010 Nov; 76(16):1892-6. PubMed ID: 20577946
[TBL] [Abstract][Full Text] [Related]
14. Rapid measurement and evaluation of the effect of drying conditions on harpagoside content in Harpagophytum procumbens (devil's claw) root.
Joubert E; Manley M; Gray BR; Schulz H
J Agric Food Chem; 2005 May; 53(9):3493-502. PubMed ID: 15853393
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterases inhibitory and antioxidant activities of Harpagophytum procumbens from in vitro systems.
Georgiev MI; Alipieva K; Orhan IE
Phytother Res; 2012 Feb; 26(2):313-6. PubMed ID: 21721061
[TBL] [Abstract][Full Text] [Related]
16. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation.
Huang TH; Tran VH; Duke RK; Tan S; Chrubasik S; Roufogalis BD; Duke CC
J Ethnopharmacol; 2006 Mar; 104(1-2):149-55. PubMed ID: 16203115
[TBL] [Abstract][Full Text] [Related]
17. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
[TBL] [Abstract][Full Text] [Related]
18. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo.
Loew D; Möllerfeld J; Schrödter A; Puttkammer S; Kaszkin M
Clin Pharmacol Ther; 2001 May; 69(5):356-64. PubMed ID: 11372004
[TBL] [Abstract][Full Text] [Related]
19. The interaction potential of herbal medicinal products: a luminescence-based screening platform assessing effects on cytochrome P450 and its use with devil's claw (Harpagophyti radix) preparations.
Modarai M; Suter A; Kortenkamp A; Heinrich M
J Pharm Pharmacol; 2011 Mar; 63(3):429-38. PubMed ID: 21749392
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
